Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Neuropace, Inc.

NPCENASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 18, 2026Accepted Nov 18, 2026, 5:09 PM ESTFiling CIK 1528287Accession 0001628280-26-074869
Share

Structured filing — 4

wk-form4_1795039777.xml

Open full document ↗

Filing details

Report period
2026-11-18
Issuer
NeuroPace Inc
Issuer CIK
0001528287
Trading symbol
NPCE

Reporting owner 1

Name
Huennekens R Scott
Reporting owner CIK
0001365493
Relationship
Director
Address
C/O NEUROPACE, INC., 455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownershipTimeliness
Common Stock2026-11-18P · Form 512,500A[F1]8.2929[F2]12,500[F3]IBy Front Foot TrustE
Table key
P · Form 5
Purchase on the market or privately
A
Acquired
I
Indirect

Footnotes

F1
Purchases made in compliance with SEC Rule 10b-18 safe harbor restrictions for manner, timing, price, and volume of purchase. Purchases also complied with broker-dealer and issuer pre-clearance procedures.↩ 1
F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.2350 to $8.3657, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.↩ 1
F3
Shares owned by the Front Foot Trust. Mr. Huennekens and a member of his immediate family serve as trustees of the trust. The reporting person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.↩ 1

Signature 1

Signed
/s/ Leah Akin, Attorney-in-Fact
Date
2026-11-18

Company context

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Current securities

Recent company filings

  1. 10-Q filingNov 12, 2026
  2. Results of Operations and Financial ConditionNov 12, 2026
  3. SCHEDULE 13G/A - filed by First Light Asset Management, LLC regarding NeuroPace IncSep 4, 2026
  4. 4 filingAug 28, 2026
  5. 10-Q filingAug 11, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.